AI CuratorAI-generated
Research summary · AI summary · not yet reviewedHuman studyObservationalPeer review unconfirmed
Human Subjects Research on Serum GFAP and Age in NMOSD Diagnosis
In a study of 640 patients, serum GFAP levels and age effectively differentiated various neuromyelitis optica spectrum disorders (NMOSD), particularly AQP4-NMOSD, from other conditions like MOGAD. The study found high diagnostic accuracy measured by area under the curve (AUC), indicating strong potential for these biomarkers in clinical diagnosis.
- Most relevant to
- Neurologist, Immunologist
This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.
Why it matters
This research highlights the role of serum GFAP and patient age in improving diagnostic approaches for NMOSD, potentially enabling timely and accurate patient management.
What this does not prove
The findings are limited to differentiating NMOSD from other diseases and do not reflect treatment efficacy or direct clinical outcomes.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Observational
- Participants / samples
- 640 · total number of participants
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Yes
- Relevant MS type
- RRMS, PPMS
- Publication date
- Not reported
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Biomarkers, Other
Original sources
- Primary evidenceNew Biomarkers Help Differentiate NMOSD Types After Attack ↗
Supporting passages (11)
study phaseThis study aimed to identify patient- and disease-level determinants of sNfL and sGFAP and to evaluate their ability to support differential diagnosis in neuromyelitis optica (NMO).
study designThe diagnostic performance of sNfL and sGFAP in discriminating between NMOSD and MS subgroups was evaluated using multivariable logistic regression and area under the curve (AUC).
subjectsMETHODS: sNFL and sGFAP levels were measured in 640 patients from the OFSEP cohort (88 NMO spectrum disorder (NMOSD) with anti-aquaporin-4 antibodies [AQP4-NMOSD], 28 double-seronegative NMOSD [DN-NMOSD], 61 myelin oligodendrocyte glycoprotein antibody-associated disease [MOGAD], 64 clinically isolated syndrome [CIS], 237 relapsing-remitting MS [RRMS], and 162 primary progressive MS [PPMS]).
sample sizeMETHODS: sNFL and sGFAP levels were measured in 640 patients from the OFSEP cohort (88 NMO spectrum disorder (NMOSD) with anti-aquaporin-4 antibodies [AQP4-NMOSD], 28 double-seronegative NMOSD [DN-NMOSD], 61 myelin oligodendrocyte glycoprotein antibody-associated disease [MOGAD], 64 clinically isolated syndrome [CIS], 237 relapsing-remitting MS [RRMS], and 162 primary progressive MS [PPMS]).
sample size basisMETHODS: sNFL and sGFAP levels were measured in 640 patients from the OFSEP cohort (88 NMO spectrum disorder (NMOSD) with anti-aquaporin-4 antibodies [AQP4-NMOSD], 28 double-seronegative NMOSD [DN-NMOSD], 61 myelin oligodendrocyte glycoprotein antibody-associated disease [MOGAD], 64 clinically isolated syndrome [CIS], 237 relapsing-remitting MS [RRMS], and 162 primary progressive MS [PPMS]).
primary endpoint metAfter a recent attack (≤ 90 days), multivariate analysis revealed that sGFAP and age discriminated AQP4-NMOSD from MOGAD (AUC = 0.939 [0.910;0.982]), AQP4-NMOSD and DN-NMOSD from MOGAD (AUC = 0.863 [0.776;0.977]), and AQP4-NMOSD from all other groups (AUC = 0.950 [0.918;0.987]).
research categoriesThis study aimed to identify patient- and disease-level determinants of sNfL and sGFAP and to evaluate their ability to support differential diagnosis in neuromyelitis optica (NMO).
relevant ms typesMETHODS: sNFL and sGFAP levels were measured in 640 patients from the OFSEP cohort (88 NMO spectrum disorder (NMOSD) with anti-aquaporin-4 antibodies [AQP4-NMOSD], 28 double-seronegative NMOSD [DN-NMOSD], 61 myelin oligodendrocyte glycoprotein antibody-associated disease [MOGAD], 64 clinically isolated syndrome [CIS], 237 relapsing-remitting MS [RRMS], and 162 primary progressive MS [PPMS]).
follow upAfter a recent attack (≤ 90 days), multivariate analysis revealed that sGFAP and age discriminated AQP4-NMOSD from MOGAD (AUC = 0.939 [0.910;0.982]), AQP4-NMOSD and DN-NMOSD from MOGAD (AUC = 0.863 [0.776;0.977]), and AQP4-NMOSD from all other groups (AUC = 0.950 [0.918;0.987]).
findingsAfter a recent attack (≤ 90 days), multivariate analysis revealed that sGFAP and age discriminated AQP4-NMOSD from MOGAD (AUC = 0.939 [0.910;0.982]), AQP4-NMOSD and DN-NMOSD from MOGAD (AUC = 0.863 [0.776;0.977]), and AQP4-NMOSD from all other groups (AUC = 0.950 [0.918;0.987]).
limitationsTitle: Serum GFAP and Age Accurately Distinguish AQP4-IgG Positive and Double Seronegative NMOSD From MOGAD After a Recent Attack.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.